论文部分内容阅读
目的探讨宫颈癌Ⅱ期患者根治术前行新辅助介入化疗的疗效。方法宫颈癌42例Ⅱ期患者,均行根治术治疗。分为两组,行术前介入化疗为治疗组(22例),行术前静脉化疗为对照组(20例)。比较两组临床疗效、生活质量及不良反应。结果治疗组总有效率、疾病控制率显著高于对照组(P<0.05);治疗组生活质量提高,有效率为95.5%(21/22),对照组为75.0%(15/20),两组比较在统计学差异有意义(P<0.05);两组术后不良反应治疗组显著低于对照组(P<0.05)。结论宫颈癌Ⅱ期患者根治术前行新辅助介入化疗,可以提高临床总有效率,提高患者生活质量,同时减少不良反应发生率。
Objective To investigate the effect of neoadjuvant interventional chemotherapy before radical hysterectomy in patients with cervical cancer. Methods 42 patients with stage Ⅱ cervical cancer were treated with radical mastectomy. Divided into two groups, preoperative intervention chemotherapy for the treatment group (22 cases), preoperative intravenous chemotherapy for the control group (20 cases). The clinical efficacy, quality of life and adverse reactions of the two groups were compared. Results The total effective rate and disease control rate in the treatment group were significantly higher than those in the control group (P <0.05). The quality of life of the treatment group was improved, the effective rate was 95.5% (21/22) and that of the control group was 75.0% (15/20) The difference between the two groups was statistically significant (P <0.05). The postoperative adverse reactions in both groups were significantly lower than those in the control group (P <0.05). Conclusions The neoadjuvant interventional chemotherapy before radical hysterectomy in patients with stage Ⅱ cervical cancer can improve the total effective rate of the patients, improve the quality of life of patients and reduce the incidence of adverse reactions.